CH562612A5 - Antigens prepd by lyophilisation and heating - Google Patents
Antigens prepd by lyophilisation and heatingInfo
- Publication number
- CH562612A5 CH562612A5 CH916968A CH916968A CH562612A5 CH 562612 A5 CH562612 A5 CH 562612A5 CH 916968 A CH916968 A CH 916968A CH 916968 A CH916968 A CH 916968A CH 562612 A5 CH562612 A5 CH 562612A5
- Authority
- CH
- Switzerland
- Prior art keywords
- inactivation
- vaccine
- days
- test
- inactivated
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract description 4
- 108091007433 antigens Proteins 0.000 title abstract description 4
- 102000036639 antigens Human genes 0.000 title abstract description 4
- 238000010438 heat treatment Methods 0.000 title abstract description 3
- 238000004108 freeze drying Methods 0.000 title abstract 2
- 230000002779 inactivation Effects 0.000 claims abstract description 39
- 241000711798 Rabies lyssavirus Species 0.000 claims abstract description 17
- 229960005486 vaccine Drugs 0.000 abstract description 41
- 238000000034 method Methods 0.000 abstract description 29
- 239000000463 material Substances 0.000 abstract description 25
- 239000000126 substance Substances 0.000 abstract description 22
- 208000015181 infectious disease Diseases 0.000 abstract description 16
- 239000003381 stabilizer Substances 0.000 abstract description 15
- 230000002458 infectious effect Effects 0.000 abstract description 12
- 244000005700 microbiome Species 0.000 abstract description 12
- 108010002885 Polygeline Proteins 0.000 abstract description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract description 7
- 229920000159 gelatin Polymers 0.000 abstract description 7
- 229930195712 glutamate Natural products 0.000 abstract description 7
- 239000008273 gelatin Substances 0.000 abstract description 6
- 235000019322 gelatine Nutrition 0.000 abstract description 6
- 108010010803 Gelatin Proteins 0.000 abstract description 5
- 235000011852 gelatine desserts Nutrition 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 229930006000 Sucrose Natural products 0.000 abstract description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 3
- 229920000642 polymer Polymers 0.000 abstract description 3
- 239000005720 sucrose Substances 0.000 abstract description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 abstract description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 abstract description 2
- 239000008103 glucose Substances 0.000 abstract description 2
- 238000005057 refrigeration Methods 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 abstract 1
- 235000008476 powdered milk Nutrition 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 32
- 239000000243 solution Substances 0.000 description 24
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 16
- 241000700605 Viruses Species 0.000 description 13
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 230000000415 inactivating effect Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 229960003127 rabies vaccine Drugs 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010037742 Rabies Diseases 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000944 nerve tissue Anatomy 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 241000539677 Berant virus Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20161—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1617350A DE1617350C3 (de) | 1967-06-22 | 1967-06-22 | Verfahren zur Inaktivierung von biologischem Material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH562612A5 true CH562612A5 (en) | 1975-06-13 |
Family
ID=6986788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH916968A CH562612A5 (en) | 1967-06-22 | 1968-06-20 | Antigens prepd by lyophilisation and heating |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS494932B1 (enrdf_load_stackoverflow) |
| AT (1) | AT279041B (enrdf_load_stackoverflow) |
| BE (1) | BE717053A (enrdf_load_stackoverflow) |
| BR (1) | BR6800054D0 (enrdf_load_stackoverflow) |
| CH (1) | CH562612A5 (enrdf_load_stackoverflow) |
| DE (1) | DE1617350C3 (enrdf_load_stackoverflow) |
| FR (2) | FR1588829A (enrdf_load_stackoverflow) |
| IL (1) | IL30206A (enrdf_load_stackoverflow) |
| LU (1) | LU56297A1 (enrdf_load_stackoverflow) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2748132A1 (de) * | 1977-10-27 | 1979-05-03 | Behringwerke Ag | Stabilisator fuer polysaccharid |
| US4456590B2 (en) * | 1981-11-02 | 1989-05-30 | Heat treatment of lyphilized blood clotting factor viii concentrate | |
| JPS6013718A (ja) * | 1983-07-05 | 1985-01-24 | Chemo Sero Therapeut Res Inst | Ｂ型肝炎ワクチン |
| JPS6122331U (ja) * | 1984-07-16 | 1986-02-08 | マルコン電子株式会社 | 回転機用コンデンサ |
| JPS6286707A (ja) * | 1985-10-02 | 1987-04-21 | アテシ | 高電圧高エネルギ−密度コンデンサ |
| FR2814957B1 (fr) * | 2000-10-06 | 2002-12-20 | Aventis Pasteur | Composition vaccinale et procede de stabilisation |
-
1967
- 1967-06-22 DE DE1617350A patent/DE1617350C3/de not_active Expired
-
1968
- 1968-06-19 IL IL30206A patent/IL30206A/en unknown
- 1968-06-19 LU LU56297D patent/LU56297A1/xx unknown
- 1968-06-20 CH CH916968A patent/CH562612A5/de not_active IP Right Cessation
- 1968-06-20 AT AT590668A patent/AT279041B/de not_active IP Right Cessation
- 1968-06-21 BR BR200054/68A patent/BR6800054D0/pt unknown
- 1968-06-22 JP JP43043344A patent/JPS494932B1/ja active Pending
- 1968-06-24 BE BE717053D patent/BE717053A/xx unknown
- 1968-06-24 FR FR1588829D patent/FR1588829A/fr not_active Expired
- 1968-09-20 FR FR167016A patent/FR8086M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| BR6800054D0 (pt) | 1973-02-13 |
| FR1588829A (enrdf_load_stackoverflow) | 1970-03-16 |
| JPS494932B1 (enrdf_load_stackoverflow) | 1974-02-04 |
| DE1617350A1 (de) | 1971-03-25 |
| IL30206A (en) | 1972-05-30 |
| FR8086M (enrdf_load_stackoverflow) | 1970-07-20 |
| DE1617350B2 (de) | 1979-01-11 |
| DE1617350C3 (de) | 1979-09-06 |
| BE717053A (enrdf_load_stackoverflow) | 1968-12-24 |
| AT279041B (de) | 1970-02-25 |
| IL30206A0 (en) | 1968-08-22 |
| LU56297A1 (enrdf_load_stackoverflow) | 1970-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2421083C2 (de) | Impfstoffe und Verfahren zu ihrer Herstellung | |
| DE3781104T2 (de) | Pasteurisierung von immunoglobulinloesungen. | |
| DE2817891A1 (de) | Nd-impfstoff und verfahren zu seiner herstellung | |
| DE3781962T2 (de) | Verfahren zur hitzebehandlung von chemisch unmodifiziertem gamma-globulin. | |
| CH562612A5 (en) | Antigens prepd by lyophilisation and heating | |
| DE2323847C3 (de) | Lebendimpfstoff zur Immunisierung von Rindern gegen die Parainfluenza-3-Virus-Infektion | |
| DE2445819A1 (de) | Verfahren zur herstellung stabiler, gegen seruminhibitoren resistenter h tief 3 n tief 2 -influenzavirusstaemme und diese virusstaemme enthaltende vakzinen | |
| DE2262427C3 (de) | Immunostimulierendes Mittel | |
| DE1617545C2 (de) | Verwendung von informatorischer Ribonucleinsäure als Vaccine | |
| DE3122669A1 (de) | "verfahren zur herstellung von neuen mutanten von herpes simplex-viren typ 1 und typ 2" | |
| CH423095A (de) | Verfahren zur Herstellung eines Tollwutimpfstoffes | |
| DE2528584A1 (de) | Verfahren zur inaktivierung der virusinfektiositaet unter gleichzeitiger stabilisierung von virusantigenen | |
| DE1950774A1 (de) | Heteroploide Zellinien | |
| DE1792256C3 (de) | Oral applizierbare, polyvalente Impfstoffe gegen lokale Darminfektionen | |
| DE60037907T2 (de) | Verfahren zur inaktivierung von mikroorganismen | |
| DE1492243C3 (de) | Injizierbare Impfstoffe | |
| CH630807A5 (de) | Verfahren zur herstellung eines antiserums. | |
| DE60213785T2 (de) | Saponin inaktivierte mykoplasma impfstoffe | |
| DE3816139A1 (de) | Verfahren zur herstellung von paramunitaetsinducern | |
| DE1246167B (de) | Verfahren zur Herstellung von Influenza-Vaccinen | |
| DE940315C (de) | Verfahren zur Herstellung von Lymphe gegen Schweinepest | |
| AT234902B (de) | Verfahren zur Herstellung einer Vaccine gegen Staupe | |
| DE2340911A1 (de) | Tetanus-antigen und verfahren zu seiner herstellung | |
| DE943312C (de) | Verfahren zur Herstellung von Vakzinen, die zur Gewinnung von Seren verwendet werden koennen | |
| AT233167B (de) | Verfahren zur Herstellung eines Impfstoffes zur gleichzeitigen Immunisierung von Hunden oder Füchsen gegen Staupe und Hepatitis contagiosa canis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |